Lenzing Valuation
Is LNZ undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of LNZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: LNZ (€29.6) is trading below our estimate of fair value (€89.32)
Significantly Below Fair Value: LNZ is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for LNZ?
Key metric: As LNZ is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is LNZ's PS Ratio? | |
|---|---|
| PS Ratio | 0.4x |
| Sales | €2.61b |
| Market Cap | €1.14b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.1x |
| Enterprise Value/EBITDA | 11x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does LNZ's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.5x | ||
MMK Mayr-Melnhof Karton | 0.3x | 3.5% | €1.4b |
AMAG AMAG Austria Metall | 0.6x | 5.6% | €825.2m |
VOE Voestalpine | 0.2x | 0.4% | €3.1b |
WIE Wienerberger | 0.7x | 6.8% | €3.0b |
LNZ Lenzing | 0.4x | 2.7% | €1.1b |
Price-To-Sales vs Peers: LNZ is good value based on its Price-To-Sales Ratio (0.4x) compared to the peer average (0.5x).
Price to Sales Ratio vs Industry
How does LNZ's PS Ratio compare vs other companies in the European Chemicals Industry?
| 27 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 27 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: LNZ is good value based on its Price-To-Sales Ratio (0.4x) compared to the European Chemicals industry average (1x).
Price to Sales Ratio vs Fair Ratio
What is LNZ's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.4x |
| Fair PS Ratio | 0.3x |
Price-To-Sales vs Fair Ratio: LNZ is expensive based on its Price-To-Sales Ratio (0.4x) compared to the estimated Fair Price-To-Sales Ratio (0.3x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €29.60 | €33.14 +12.0% | 3.6% | €35.00 | €32.00 | n/a | 5 |
| Nov ’25 | €31.60 | €34.04 +7.7% | 2.6% | €35.00 | €32.70 | n/a | 5 |
| Oct ’25 | €34.60 | €34.04 -1.6% | 2.6% | €35.00 | €32.70 | n/a | 5 |
| Sep ’25 | €30.85 | €34.04 +10.3% | 2.6% | €35.00 | €32.70 | n/a | 5 |
| Aug ’25 | €31.85 | €34.26 +7.6% | 2.7% | €35.00 | €32.80 | n/a | 5 |
| Jul ’25 | €33.20 | €34.26 +3.2% | 2.7% | €35.00 | €32.80 | n/a | 5 |
| Jun ’25 | €34.80 | €34.26 -1.6% | 2.7% | €35.00 | €32.80 | n/a | 5 |
| May ’25 | €30.35 | €31.26 +3.0% | 11.3% | €35.00 | €25.00 | n/a | 5 |
| Apr ’25 | €32.05 | €32.26 +0.7% | 11.6% | €35.00 | €25.00 | n/a | 5 |
| Mar ’25 | €29.70 | €36.66 +23.4% | 12.0% | €45.00 | €32.80 | n/a | 5 |
| Feb ’25 | €30.15 | €40.80 +35.3% | 13.2% | €45.50 | €33.50 | n/a | 5 |
| Jan ’25 | €35.55 | €43.60 +22.6% | 5.5% | €45.50 | €39.00 | n/a | 5 |
| Dec ’24 | €34.35 | €44.60 +29.8% | 7.9% | €50.00 | €39.00 | n/a | 5 |
| Nov ’24 | €36.65 | €46.33 +26.4% | 8.5% | €51.00 | €39.00 | €31.60 | 6 |
| Oct ’24 | €38.85 | €50.83 +30.8% | 20.1% | €72.00 | €39.00 | €34.60 | 6 |
| Sep ’24 | €43.55 | €50.83 +16.7% | 20.1% | €72.00 | €39.00 | €30.85 | 6 |
| Aug ’24 | €45.50 | €62.04 +36.4% | 20.3% | €74.20 | €39.00 | €31.85 | 5 |
| Jul ’24 | €44.85 | €62.04 +38.3% | 20.3% | €74.20 | €39.00 | €33.20 | 5 |
| Jun ’24 | €54.70 | €62.04 +13.4% | 20.3% | €74.20 | €39.00 | €34.80 | 5 |
| May ’24 | €59.30 | €65.04 +9.7% | 20.7% | €75.00 | €39.00 | €30.35 | 5 |
| Apr ’24 | €69.50 | €65.04 -6.4% | 20.7% | €75.00 | €39.00 | €32.05 | 5 |
| Mar ’24 | €70.50 | €74.64 +5.9% | 41.2% | €130.00 | €39.00 | €29.70 | 5 |
| Feb ’24 | €67.20 | €73.90 +10.0% | 41.6% | €130.00 | €39.00 | €30.15 | 5 |
| Jan ’24 | €54.80 | €73.90 +34.9% | 41.6% | €130.00 | €39.00 | €35.55 | 5 |
| Dec ’23 | €66.00 | €73.90 +12.0% | 41.6% | €130.00 | €39.00 | €34.35 | 5 |
| Nov ’23 | €47.85 | €78.30 +63.6% | 40.6% | €130.00 | €39.00 | €36.65 | 5 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
ArcelorMittal
€18.2b
Operates as integrated steel and mining companies in the United States, Europe, and internationally.
MT
€23.01
7D
-3.6%
1Y
2.0%
Freeport-McMoRan
US$62.5b
Engages in the mining of mineral properties in North America, South America, and Indonesia.
FCX
US$41.51
7D
0.2%
1Y
23.8%
LANXESS
€2.1b
Operates as a specialty chemicals company that engages in the development, manufacture, and marketing of chemical intermediates, additives, specialty chemicals, and consumer protection products worldwide.
LXS
€23.78
7D
2.0%
1Y
5.5%